Everolimus Combined With Gefitinib in Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I/II Results and Signaling Pathway Implications

BACKGROUND: The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in PTEN-null tumors, thus we tested the combination of mTOR inhibition (everolimus) and EGFR inhibition (gefitinib) in castration-resistant prostate c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Rathkopf, Dana E., Larson, Steven M., Anand, Aseem, Morris, Michael J., Slovin, Susan F., Shaffer, David R., Heller, Glenn, Carver, Brett, Rosen, Neal, Scher, Howard I.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618268/
https://ncbi.nlm.nih.gov/pubmed/26178426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29578
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki